Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021 May;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Koulouris A, Tsagkaris C, Spyrou V, et al. Hepatocellular carcinoma: an overview of the changing landscape of treatment options. J Hepatocell Carcinoma. 2021 Jan;8:387–401. doi: 10.2147/JHC.S300182
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589–604. doi: 10.1038/s41575-019-0186-y
   PubMed Web of Science ®Google Scholar
• Sun HC, Zhu XD. Downstaging conversion therapy in patients with initially unresectable advanced hepatocellular carcinoma: an overview. Front Oncol. 2021 Jan;11:772195. doi: 10.3389/fonc.2021.772195
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019 Jan;156(2):477–491. doi: 10.1053/j.gastro.2018.08.065
   PubMed Web of Science ®Google Scholar
• Fan Y, Xue H, Zheng H. Systemic therapy for hepatocellular carcinoma: current updates and outlook. J Hepatocell Carcinoma. 2022 Jan 20;9:233–263. doi: 10.2147/JHC.S358082
   PubMedGoogle Scholar
• Falette PM, Pellat A, Assaf A, et al. Therapeutic management of advanced hepatocellular carcinoma: an updated review. Cancers (Basel). 2022 May 10;14(10):2357. doi: 10.3390/cancers14102357
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378–390. doi: 10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25–34. doi: 10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi: 10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Sherman M. Regorafenib for treatment of hepatocellular carcinoma. Hepatology. 2018;67(3):1162–1165. doi: 10.1002/hep.29598
   PubMed Web of Science ®Google Scholar
• Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends. 2021 Jul;15(3):155–160. doi: 10.5582/bst.2021.01091
   PubMed Web of Science ®Google Scholar
• Funakoshi T, Latif A, Galsky MD. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J Hum Hypertens. 2013 Oct;27(10):601–611. doi: 10.1038/jhh.2013.30
   PubMed Web of Science ®Google Scholar
• Justice CN, Derbala MH, Baich TM, et al. The impact of pazopanib on the cardiovascular System. J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):387–398. doi: 10.1177/1074248418769612
   PubMed Web of Science ®Google Scholar
• Dobbin S, Petrie MC, Myles RC, et al. Cardiotoxic effects of angiogenesis inhibitors. Clin Sci. 2021 Jan;135(1):71–100. doi: 10.1042/CS20200305
   Web of Science ®Google Scholar
• Pinkhas D, Ho T, Smith S. Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development. Cardiooncology. 2017 Jan; 3;3(1). doi: 10.1186/s40959-017-0024-8
   PubMedGoogle Scholar
• Fan QQ, Hu Y, Yang CQ, et al. Myocarditis following the use of different immune checkpoint inhibitor regimens: a real-world analysis of post-marketing surveillance data. Int Immunopharmacol. 2019 Nov;76:105866. doi: 10.1016/j.intimp.2019.105866
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting System. Int J Med Sci. 2013 Jan;10(7):796–803. doi: 10.7150/ijms.6048
   PubMed Web of Science ®Google Scholar
• Wang YF, Cui CJ, Ren XY, et al. Cardiovascular toxicity associated with angiogenesis inhibitors: a comprehensive pharmacovigilance analysis based on the FDA adverse event reporting System database from 2014 to 2021. Front Cardiovasc Med. 2022 Jan;9:988013. doi: 10.3389/fcvm.2022.988013
   PubMed Web of Science ®Google Scholar
• Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004 Nov;127(5 Suppl 1):S5–16. doi: 10.1053/j.gastro.2004.09.011
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan;389(10064):56–66. doi: 10.1016/S0140-6736(16)32453-9
   PubMed Web of Science ®Google Scholar
• Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017 Apr;52(4):512–519. doi: 10.1007/s00535-016-1263-4
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Longo DL. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016 Oct;375(15):1457–1467. doi: 10.1056/NEJMra1100265
   PubMed Web of Science ®Google Scholar
• Li W, Croce K, Steensma DP, et al. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol. 2015 Sep;66(10):1160–1178. doi: 10.1016/j.jacc.2015.07.025
   PubMed Web of Science ®Google Scholar
• Rimassa L, Danesi R, Pressiani T, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev. 2019 Jul;77:20–28. doi: 10.1016/j.ctrv.2019.05.004
   PubMed Web of Science ®Google Scholar
• Wirth LJ, Tahara M, Robinson B, et al. Treatment-emergent hypertension and efficacy in the phase 3 study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer-Am Cancer Soc. 2018 Jun;124(11):2365–2372. doi: 10.1002/cncr.31344
   Google Scholar
• Yuan X, Mitsis A, Nienaber CA. Current understanding of aortic dissection. Life. 2022 Oct;12(10):1606. doi: 10.3390/life12101606
   PubMedGoogle Scholar
• Tsuchiya A, Ogawa M, Watanabe Y, et al. Successful treatment of aortic dissection during sorafenib therapy for hepatocellular carcinoma. Clin Case Rep. 2018 Aug;6(8):1643–1644. doi: 10.1002/ccr3.1674
   PubMed Web of Science ®Google Scholar
• Takada M, Yasui T, Oka T, et al. Aortic dissection and cardiac dysfunction emerged coincidentally during the long-term treatment with angiogenesis inhibitors for metastatic renal cell carcinoma. Int Heart J. 2018 Sep;59(5):1174–1179. doi: 10.1536/ihj.17-461
   PubMed Web of Science ®Google Scholar
• Zhou Z, Cecchi AC, Prakash SK, et al. Risk factors for thoracic aortic dissection. Genes (Basel). 2022 Oct;13(10):1814. doi: 10.3390/genes13101814
   PubMed Web of Science ®Google Scholar
• Dorks M, Jobski K, Herget-Rosenthal S, et al. Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection-A pharmacovigilance analysis. Pharmacol Res Perspect. 2021 Feb;9(1):e707. doi: 10.1002/prp2.707
   Web of Science ®Google Scholar
• Hatem R, Bebawi E, Schampaert E. Potential sunitinib-induced coronary artery and aortic dissections. Can J Cardiol. 2017 Jun;33(6):817–830. doi: 10.1016/j.cjca.2017.03.002
   Web of Science ®Google Scholar
• Niwa N, Nishiyama T, Ozu C, et al. Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib. Acta Oncol. 2015 Apr;54(4):561–562. doi: 10.3109/0284186X.2014.963887
   PubMed Web of Science ®Google Scholar
• Bonnet C, Sibon I. Potential role of anti-VEGF targeted therapies in cervical artery dissection: a case report. Rev Neurol (Paris). 2015 Sep;171(8–9):677–679. doi: 10.1016/j.neurol.2015.03.010
   PubMed Web of Science ®Google Scholar
• Bronte G, Bronte E, Novo G, et al. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Expert Opin Drug Saf. 2015 Feb;14(2):253–267. doi: 10.1517/14740338.2015.986092
   PubMed Web of Science ®Google Scholar
• Chintalgattu V, Ai D, Langley RR, et al. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest. 2010 Feb;120(2):472–484. doi: 10.1172/JCI39434
   PubMed Web of Science ®Google Scholar
• Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. 2018 Jan;2:13. doi: 10.1038/s41698-018-0056-z
   PubMed Web of Science ®Google Scholar
• Scott SS, Greenlee AN, Matzko A, et al. Intracellular signaling pathways mediating tyrosine kinase inhibitor Cardiotoxicity. Heart Fail Clin. 2022 Jul;18(3):425–442. doi: 10.1016/j.hfc.2022.02.003
   PubMed Web of Science ®Google Scholar
• Kivela R, Hemanthakumar KA, Vaparanta K, et al. Endothelial cells regulate physiological cardiomyocyte growth via VEGFR2-mediated paracrine signaling. Circulation. 2019 May;139(22):2570–2584. doi: 10.1161/CIRCULATIONAHA.118.036099
   PubMed Web of Science ®Google Scholar
• Takagi K, Takai M, Kawata K, et al. [Three patients with acute myocardial infarction associated with targeted therapy of sorafenib for metastatic renal cell carcinoma: case report]. Hinyokika Kiyo. 2015 Sep;61(9):347–351.
   PubMedGoogle Scholar
• Paschke L, Lincke T, Muhlberg K, et al. Myocardial infarction after long-term treatment with a tyrosine kinase inhibitor (TKI) with anti-VEGF receptor activity. Case Rep Endocrinol. 2019 Jan;2019:7927450. doi: 10.1155/2019/7927450
   PubMed Web of Science ®Google Scholar
• Duran JM, Makarewich CA, Trappanese D, et al. Sorafenib cardiotoxicity increases mortality after myocardial infarction. Circ Res. 2014 May;114(11):1700–1712. doi: 10.1161/CIRCRESAHA.114.303200
   PubMed Web of Science ®Google Scholar
• Petrini I, Lencioni M, Ricasoli M, et al. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2012 Mar;69(3):773–780. doi: 10.1007/s00280-011-1753-2
   PubMed Web of Science ®Google Scholar
• Lu Z, Wu CY, Jiang YP, et al. Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci Transl Med. 2012 Apr;4(131):131r–150r. doi: 10.1126/scitranslmed.3003623
   Web of Science ®Google Scholar